Search
MKC1106-PP
go.drugbank.com/drugs/DB06030ExperimentalMKC1106-PP is a 3-component investigational vaccine made up of a DNA plasmid (pPRA-PSM) and 2 peptides E-PRA and E-PSM.
R343
go.drugbank.com/drugs/DB06316InvestigationalR343, was investigated in clinical trial NCT01591044 to evaluate its safety and efficacy in patients with mild to moderate asthma.
Tamibarotene
go.drugbank.com/drugs/DB04942InvestigationalTamibarotene is a novel synthetic retinoid for acute promyelocytic leukaemia (APL). Tamibarotene is currently approved in Japan for treatment of recurrent APL, and is undergoing clinical trials in the United States.
E-2012
go.drugbank.com/drugs/DB05171ExperimentalE-2012 is a gamma secretase modulator that is being evaluated as a potential new treatment for Alzheimer's disease.
AAV-dXIAP
go.drugbank.com/drugs/DB17880ExperimentalAAV-dXIAP is a recombinant adeno-associated virus-encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP) developed by Neurologix.
CEQ508
go.drugbank.com/drugs/DB17911ExperimentalCEQ508 is a Live Attenuated E. Coli Expressing Beta Catenin ShRNA currently being investigated to treat Familial Adenomatous Polyposis.
GMI-1359
go.drugbank.com/drugs/DB18092InvestigationalGMI-1359 is a small molecule, glycomimetic compound with dual inhibitory activity against E-selectin and CXCR4.[A261406]
OCU400
go.drugbank.com/drugs/DB18277InvestigationalOCU400 is a novel gene therapy comprising an adeno-associated viral vector expressing human nuclear hormone receptor subfamily 2 group E member 3 (hNR2E3).
PF-05230907
go.drugbank.com/drugs/DB18417InvestigationalPF-05230907 is a recombinant activated Factor X variant.
Zilovertamab vedotin
go.drugbank.com/drugs/DB18457Investigationalconjugate (ADC) comprising an anti-ROR1 monoclonal antibody (UC-961), a proteolytically cleavable maleimidocaproyl-valine-citrulline-para-aminobenzoate linker (mc-vc-PAB), and a monomethyl auristatin E